- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05448066
Molecular Allergen Component Resolved Diagnosis to Decide Immunotherapy (CRD-AIT)
Molecular Allergen Based Diagnosis Impact on Clinical Efficacy of Aeroallergen Immunotherapy- a Pragmatic Randomized Clinical Trial
Allergen immunotherapy (AIT) is used for the control of allergic diseases that are not completely responsive to avoidance strategies and/or pharmacotherapy. It is also considered the main treatment with the potential to modify allergic disease evolution. It's efficacy and safety in allergic rhinitis and asthma is supported by large systematic reviews and is recommended as a cornerstone treatment option in allergic disease. Molecular based allergy diagnosis has greatly evolved and the knowledge of molecular allergen sensitization pattern has been used to better define the allergen extract composition of AIT. However, uncertainty remains if this strategy is related to an increase of efficacy. Regulation of allergen extracts for allergen immunotherapy are currently underway in Europe, but there is still lack of standardization of relevant allergens and important differences are seen between allergenic contents.
Therefore, we aim to evaluate, in a real-life setting, the impact of using molecular-based diagnosis versus standard diagnostic tools in the efficacy of aeroallergen immunotherapy, using a pragmatic randomized controlled trial design and also to address the impact of the discrepancy between individual aeroallergen sensitization profiles and the major allergen molecular content of aeroallergen immunotherapy.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Diana M Silva, PhD
- Phone Number: 964021365
- Email: dianapereirasilva@chsj.min-saude.pt
Study Locations
-
-
-
Porto, Portugal
- Recruiting
- Faculty of Medicine Porto University/Centro Hospitalar de São João
-
Contact:
- Diana Silva, PhD
- Phone Number: 964021365
-
Principal Investigator:
- Diana Silva, PhD
-
Sub-Investigator:
- Maria João Vasconcelos
-
Sub-Investigator:
- Daniela Brandão
-
Sub-Investigator:
- Mariana Bragança
-
Sub-Investigator:
- Diogo Mota
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Individuals with medical indication for aeroallergen immunotherapy(AIT) for allergic rhinoconjunctivitis or asthma, accordingly to the AIT guidelines;
- Over 5 years of age;
- Evidence of IgE-sensitization (positive skin prick tests and / or serum specific-IgE)
- Patients have indication to AIT to house dust mites and/or grass pollen, association with other allergens is not an exclusion criteria
Exclusion Criteria:
- Previously performed allergen immunotherapy
- Need the use of molecular allergen diagnosis to decide treatment and diagnostic strategy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Standard diagnosis
Patients followed in the allergy clinic with indication for allergen immunotherapy using only standard diagnosis.
|
Physicians will only have access to standard diagnostic tools namely skin prick tests and sIgE sensitization (not molecular IgE) and clinical history.
|
EXPERIMENTAL: CRD diagnosis
Patients followed in the allergy clinic with indication for allergen immunotherapy decided with standard diagnostic tools and molecular based diagnosis.
|
Physicians in this group will have access to allergen molecular component sensitization profile, using ImmunoCAP ISAC E112i and to all standard diagnostic tolls
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of combined symptom and medication score (CSMS) at 52 weeks
Time Frame: 0 to 52 weeks
|
Differences, in the mean change at 52 weeks, of CSMS between groups that were treated with AIT in the component resolved diagnosis versus standard diagnosis groups.
CSMS is the sum of the daily symptom score (dSS, score 0 to 3) plus daily medication score (dMS; score 0 to 6)
|
0 to 52 weeks
|
Change of combined symptom and medication score (CSMS) at 24 weeks
Time Frame: 0 to 24 weeks
|
Difference, in the mean change at 24 weeks, of CSMS between groups were treated with AIT in the component resolved diagnosis versus standard diagnosis groups.
|
0 to 24 weeks
|
Change of rhinitis symptoms using visual analogue scale at 52 weeks
Time Frame: 0 to 52 weeks
|
Difference between groups(control vs intervention) in the mean change at 52 weeks, in the psychometric response scale.
This scale is used to assess rhinoconjunctivitis discomfort and its impacts on symptom severity and need of treatment.
|
0 to 52 weeks
|
Change of rhinitis symptoms using visual analogue scale at 24 weeks
Time Frame: 0 to 24 weeks
|
Difference between groups(control vs intervention) in the mean change at 52 weeks, in the psychometric response scale.
This scale is used to assess rhinoconjunctivitis discomfort and its impacts on symptom severity and need of treatment.
|
0 to 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Control of Allergic Rhinitis and Asthma Test (CARAT) at 52 weeks
Time Frame: 0 to 52 weeks
|
Differences between groups (control vs intervention) in the mean change at 52 weeks in the scores obtained on the self-administered Portuguese validated questionnaire that assess symptoms and control of both allergic rhinitis and asthma in the previous 4 weeks.
The final score ranges from 0 to 30, with scores over 24 indicating good control of asthma and allergic rhinitis, a four-point changes will be considered the minimal important difference
|
0 to 52 weeks
|
Change in Control of Allergic Rhinitis and Asthma Test (CARAT) at 24 weeks
Time Frame: 0 to 24 weeks
|
Differences between groups (control vs intervention) in the mean change at 24 weeks in the scores obtained on the self-administered Portuguese validated questionnaire that assess symptoms and control of both allergic rhinitis and asthma in the previous 4 weeks.
The final score ranges from 0 to 30, with scores over 24 indicating good control of asthma and allergic rhinitis, a four-point changes will be considered the minimal important difference.
|
0 to 24 weeks
|
Change in Asthma Control Test (ACT) at 52 weeks
Time Frame: 0 to 52 weeks
|
Differences between control and intervention group of change in the self-report questionnaire regarding asthma symtoms that includes 5 items assessing each of the following for the previous 4 weeks.
ACT score ranges from 5 (poor control of asthma) to 25 (complete control of asthma)
|
0 to 52 weeks
|
Change in Asthma Control Test (ACT) at 24 weeks
Time Frame: 0 to 24 weeks
|
Differences between control and intervention group of change in the self-report questionnaire regarding asthma symtoms that includes 5 items assessing each of the following for the previous 4 weeks.
ACT score ranges from 5 (poor control of asthma) to 25 (complete control of asthma)
|
0 to 24 weeks
|
Change in quality of life related with rhinitis and asthma at 52 weeks
Time Frame: 0 to 52 weeks
|
Difference between groups regarding self-administered version of Rhinoconjunctivitis Quality of Life Questionnaire which is validated in Portuguese for patients over 12 years at 52 weeks.
A change greater than 0.5 will be considered a critically clinically significant difference
|
0 to 52 weeks
|
Change in quality of life related with rhinitis and asthma at 24 weeks
Time Frame: 0 to 24 weeks
|
Differences between groups regarding the self-administered version of Rhinoconjunctivitis Quality of Life Questionnaire which is validated in Portuguese for patients over 12 years at 24 weeks.
A change greater than 0.5 will be considered a critically clinically significant difference
|
0 to 24 weeks
|
Change in ESPIA score- patient reported opinion allergen immunotherapy at 52 weeks
Time Frame: 0 to 52 weeks
|
Differences between intervention and control groups in the self-administered questionnaire with 16 questions distributed in 4 dimensions: perception of effectiveness, activities and environment, cost-benefit balance and general satisfaction at 52 weeks
|
0 to 52 weeks
|
Change in ESPIA score- patient reported opinion allergen immunotherapy at 24 weeks
Time Frame: 0 to 24 weeks
|
Differences in the self-administered questionnaire with 16 questions distributed in 4 dimensions: perception of effectiveness, activities and environment, cost-benefit balance and general satisfaction at 24 weeks
|
0 to 24 weeks
|
Change in the cost impact between groups
Time Frame: 0 and 52 weeks
|
Direct and indirect healthcare related costs will be assessed in each of the groups before and after treatment and compared
|
0 and 52 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Diana Silva, Faculty of Medicine Porto University
Publications and helpful links
General Publications
- Roberts G, Pfaar O, Akdis CA, Ansotegui IJ, Durham SR, Gerth van Wijk R, Halken S, Larenas-Linnemann D, Pawankar R, Pitsios C, Sheikh A, Worm M, Arasi S, Calderon MA, Cingi C, Dhami S, Fauquert JL, Hamelmann E, Hellings P, Jacobsen L, Knol EF, Lin SY, Maggina P, Mosges R, Oude Elberink JNG, Pajno GB, Pastorello EA, Penagos M, Rotiroti G, Schmidt-Weber CB, Timmermans F, Tsilochristou O, Varga EM, Wilkinson JN, Williams A, Zhang L, Agache I, Angier E, Fernandez-Rivas M, Jutel M, Lau S, van Ree R, Ryan D, Sturm GJ, Muraro A. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018 Apr;73(4):765-798. doi: 10.1111/all.13317. Epub 2017 Oct 30.
- Matricardi PM, Dramburg S, Potapova E, Skevaki C, Renz H. Molecular diagnosis for allergen immunotherapy. J Allergy Clin Immunol. 2019 Mar;143(3):831-843. doi: 10.1016/j.jaci.2018.12.1021.
- Dhami S, Nurmatov U, Arasi S, Khan T, Asaria M, Zaman H, Agarwal A, Netuveli G, Roberts G, Pfaar O, Muraro A, Ansotegui IJ, Calderon M, Cingi C, Durham S, van Wijk RG, Halken S, Hamelmann E, Hellings P, Jacobsen L, Knol E, Larenas-Linnemann D, Lin S, Maggina P, Mosges R, Oude Elberink H, Pajno G, Panwankar R, Pastorello E, Penagos M, Pitsios C, Rotiroti G, Timmermans F, Tsilochristou O, Varga EM, Schmidt-Weber C, Wilkinson J, Williams A, Worm M, Zhang L, Sheikh A. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis. Allergy. 2017 Nov;72(11):1597-1631. doi: 10.1111/all.13201. Epub 2017 Jul 14.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017-21
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
Clinical Trials on Standard diagnosis
-
University Medical Center GroningenNot yet recruitingCritically Ill | Organ Failure, Multiple
-
University Hospital, LilleRecruitingAspiration PneumoniaFrance
-
Elizabeth Glaser Pediatric AIDS FoundationUNITAIDCompletedHIV/AIDS | Infant Morbidity | Pediatric HIV Infection | Transmission, Perinatal InfectionKenya, Zimbabwe
-
Nuclear Medicine Consultants, Inc.Unknown
-
First Affiliated Hospital Xi'an Jiaotong UniversityNot yet recruiting
-
Singapore Chung Hwa Medical InstitutionMinistry of Health, SingaporeRecruitingHypertension | Healthy | Diabete Mellitus | Pre-diabetes | Dyslipidemia Associated With Type II Diabetes MellitusSingapore
-
Hospices Civils de LyonActive, not recruiting
-
IsalaCompleted
-
Beijing Tiantan HospitalWest China Hospital; The First Affiliated Hospital of Zhengzhou University; Capital... and other collaboratorsNot yet recruiting
-
Yeditepe UniversityCompleted